Dr. Victor Lewis, MD
Claim this profileAlberta Children's Hospital
About Victor Lewis, MD
Education:
- Completed medical training in Pakistan.
Experience:
- Served as an internist before specializing further.
- Retrained in Pediatrics, Pediatric Hematology/Oncology, and Transplantation at the University of Minnesota, USA.
- Has been with the University of Calgary and Alberta Children's Hospital since 2002, focusing on pediatric leukemia, lymphoma, and transplantation.
- Currently the Director of the Oncology and Blood and Marrow Transplant sections at Alberta Children's Hospital.
- Co-leads both the Phase I/II program and the developmental therapeutics program at the institution.
Area of expertise
Cancer
Victor Lewis, MD has run 6 trials for Cancer. Some of their research focus areas include:
Acute Lymphoblastic Leukemia
Victor Lewis, MD has run 5 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Alberta Children's Hospital
Alberta Children's Hospital (Adults And Pediatrics)
Clinical Trials Victor Lewis, MD is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protein that can bind to certain targets on the surface of cells. Inotuzumab ozogamicin is a monoclonal antibody that is linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells by binding to the CD22 protein on the surface of the cancer cell and delivering calicheamicin inside the cells to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Blinatumomab is a specialized type of monoclonal antibody known as a bispecific T-cell engager (BiTE). It works by simultaneously binding to CD19 on cancer cells and CD3 on normal immune cells, bringing them together to destroy leukemia cells. Blinatumomab is a standard part of chemo-immunotherapy treatment for B-ALL. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin or blinatumomab. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemo-immunotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first phase of therapy: Induction. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-induction treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (consolidation, blinatumomab block 1, interim maintenance 1, blinatumomab block 2, delayed intensification, interim maintenance 2, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of consolidation or part of delayed intensification. Other aims of this study include evaluating 1) side effects of treatment using patient-reported outcomes and health-related quality of life, 2) the best ways to help patients adhere to oral chemotherapy regimens, 3) the relationship between levels of inotuzumab ozogamicin in the blood and side effects, 4) the impact of chemo-immunotherapy on the immune system and risk of infection, and 5) the impact of social determinants of health on outcomes. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Tabelecleucel
for Post-Transplant Cancer
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Recruiting
2 awards
Phase 3
12 criteria
More about Victor Lewis, MD
Clinical Trial Related
6 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 14 Active Clinical Trials
Treatments Victor Lewis, MD has experience with
- Cyclophosphamide
- Etoposide
- Radiation Therapy
- Vincristine Sulfate
- Carboplatin
- Dexamethasone
Breakdown of trials Victor Lewis, MD has run
Cancer
Acute Lymphoblastic Leukemia
Leukemia
Biphenotypic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Victor Lewis, MD specialize in?
Victor Lewis, MD focuses on Cancer and Acute Lymphoblastic Leukemia. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Victor Lewis, MD currently recruiting for clinical trials?
Yes, Victor Lewis, MD is currently recruiting for 14 clinical trials in Calgary Alberta. If you're interested in participating, you should apply.
Are there any treatments that Victor Lewis, MD has studied deeply?
Yes, Victor Lewis, MD has studied treatments such as Cyclophosphamide, Etoposide, Radiation Therapy.
What is the best way to schedule an appointment with Victor Lewis, MD?
Apply for one of the trials that Victor Lewis, MD is conducting.
What is the office address of Victor Lewis, MD?
The office of Victor Lewis, MD is located at: Alberta Children's Hospital, Calgary, Alberta T3A 6A8 Canada. This is the address for their practice at the Alberta Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.